

Supplementary Data

SUPPLEMENTARY TABLE S1. COHORT DEMOGRAPHICS, CLINICAL CHARACTERISTICS, AND WEIGHT GAIN AT 1 AND 3 YEARS OF ANTIRETROVIRAL THERAPY STRATIFIED BY YEAR OF ANTIRETROVIRAL THERAPY INITIATION IN NA-ACCORD, 1998–2010

	1998–2000 n = 2269	2001–2003 n = 2856	2004–2006 n = 2958	2007–2010 n = 5664	p-value
Cohort at ART initiation					
Female, %	14%	17%	18%	17%	0.006
Nonwhite race, %	51%	56%	57%	61%	<0.001
Age, median years (IQR)	38 (33, 44)	39 (34, 45)	41 (34, 47)	41 (32, 48)	<0.001
Overweight (BMI 25.0–29.9 kg/m ²), %	29%	30%	30%	31%	0.11
Obese (BMI ≥30 kg/m ²), %	11%	13%	15%	17%	<0.001
CD4 count, median cells/μl (IQR)	217 (60, 397)	204 (69, 332)	208 (77, 324)	278 (142, 409)	<0.001
log ₁₀ HIV viral load, median copies/ml (IQR)	4.9 (4.2, 5.5)	4.8 (4.2, 5.3)	4.8 (4.0, 5.3)	4.4 (3.2, 5.1)	<0.001
First ART regimen class					<0.001
PI based	63%	32%	53%	41%	
NNRTI based	34%	49%	44%	50%	
NRTI only	3%	18%	2%	1%	
Other	0%	0%	0%	7%	
Cohort at 1 year of ART ^a					
Weight change, kg	1.4 (−1.4, 6.0)	1.4 (−1.0, 6.0)	1.0 (−0.9, 6.0)	1.4 (−1.5, 5.4)	0.05
BMI change, kg/m ²	0.46 (−0.43, 2.00)	0.43 (−0.35, 1.97)	0.37 (−0.28, 1.95)	0.44 (−0.51, 1.78)	0.08
Cohort at 3 years of ART ^{a,b}					
Weight change, kg	1.8 (−2.0, 6.4)	1.8 (−1.4, 6.8)	2.3 (−0.9, 8.0)	NA	<0.001
BMI change, kg/m ²	0.59 (−0.65, 2.13)	0.56 (−0.42, 2.21)	0.76 (−0.28, 2.58)	NA	<0.001

^aMedian values and interquartile range.

^bThree year weight and BMI change for patients starting ART in 2007–2010 group not shown due to insufficient follow-up time.

Excludes 337 patients missing date of ART initiation.

ART, antiretroviral therapy; BMI, body mass index; IQR, interquartile range; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.